FIZE Medical Announces First Close of $20 Million Series B to Advance AI-Guided Fluid Management Platform

Breaking NewsCare & TherapyEuropeStrategic Development

FIZE Medical, an Israel-based provider of smart fluid management solutions for critically ill patients, has announced the first close of its Series B financing round co-led by Asahi Kasei Medical and Rapha Capital Management, making significant progress toward the company’s $20 million financing target. The financing comes at a pivotal point in FIZE Medical’s growth as it expands its commercial footprint and advances its next-generation FIZE Optima platform toward predictive, AI-guided clinical decision support.

Proceeds from the round will be used to accelerate development of the FIZE Optima platform for AI-driven prediction and treatment guidance and to strengthen commercial activities in FIZE Medical’s leading markets. The round marks a deepening of FIZE Medical’s strategic relationship with Asahi Kasei Medical, which launched FIZE kUO in Japan and serves as the company’s exclusive distribution partner there. Asahi Kasei Medical will now also distribute FIZE kUO in Europe, expanding FIZE Medical’s commercial reach into a major new market. With this investment, Asahi Kasei Medical is expanding its involvement beyond distribution into fluid management, signaling a deeper strategic commitment to FIZE Medical’s technology and vision for critical care.

Dror Zerem, CEO of FIZE Medical, said Asahi Kasei Medical has been an important and trusted partner in bringing FIZE kUO to clinicians in Japan, and that this investment represents a meaningful next step in the relationship. Zerem noted that the company is moving beyond monitoring toward a future in which continuous patient data can help clinicians anticipate fluid-related risk and make more informed treatment decisions, and that having Asahi Kasei Medical deepen its commitment at this stage is a powerful validation of both the technology and vision.

Shuichiro Inadome, CEO of Asahi Kasei Medical, stated that as a world leader in devices and systems for blood treatment and purification, the company already knows this space well, and fluid management is a natural extension of its presence in critical care. Inadome noted that the company is excited to deepen its partnership with FIZE Medical as it advances from precision monitoring toward predictive, AI-powered fluid management, and that it sees significant potential in FIZE’s technology.

Kevin Slawin, M.D., Founder and Managing Partner of Rapha Capital Management, said that Asahi Kasei Medical’s investment is a vote of confidence in FIZE Medical’s technology and trajectory. Slawin noted that Rapha Capital began investing in FIZE from its earliest stage because it believed in the potential to fundamentally change medicine through the kUO device, and that the firm continues that commitment as FIZE establishes the kUO as a leading device in real-time kidney urine output data collection.